1Stefan HH,Stuart JC.Combined antiplatelet therapy in atrial fibrillation:Review of the leiterature and future research avenues,[J].Cardiovasc Electrophysiol,2003,14(Suppl):S60
2Antithrombotic trialists'collaboration:Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324:71
3Hart RG,Pearce LA,Koudstaal PJ.Transient ischemic attacks in patients with atrial fibrillation-lmplications for secondary prevention:The European Atrial Fibrillation Trial and stroke prevention in Atrial Fibrillation Ⅲ Trial[J].STROKE,2004,35(4):948
4Diener HC,Cunha L,Forbes C,et al.European Stroke Prevention Study2.Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke[J].J Neurol Sci,1996,143:1
5Posada IS,Barriates V.Alternate day dosing of aspirin in atrial fibrillation[J].Am Heart J,1999,138:137
7Petersen P,Boysen G,Godtfredsen J,et al.Place-controlled,randomized trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation.The Copenhagen AFASAK Study[J].Lancet,1989,1:175
8Stroke Prevention in Atrial Fibrillation Investigators:Stroke Prevention in Atrial Fibrillation Study:Final results[J].Circulation,1991,84:527
9Robert GH,David GS.Adjusted-dose warfarin versus low-intensity,fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation:Stroke Prevention in Atrial Fibrillation III randomised clinical trial[J].Lancet,1996,348:633
